Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H13N3 |
Molecular Weight | 223.2731 |
Optical Activity | ( + ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N#CC1=CC=C(C=C1)[C@H]2CCCC3=CN=CN23
InChI
InChIKey=CLPFFLWZZBQMAO-CQSZACIVSA-N
InChI=1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2/t14-/m1/s1
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P19099 Gene ID: 1585.0 Gene Symbol: CYP11B2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20699715 |
3.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22275532
In a preclinical study, (+)-fadrozole was given to rats at a dose of 30 mg/kg.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28759940
(+)-Fadrozole inhibited angiotensin II-stimulated basal aldosterone production in NCI-H295R cells, showing a maximal effect at 10 nmol/l.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
102676-87-9
Created by
admin on Sat Dec 16 18:26:28 GMT 2023 , Edited by admin on Sat Dec 16 18:26:28 GMT 2023
|
PRIMARY | |||
|
IC1B8751F6
Created by
admin on Sat Dec 16 18:26:28 GMT 2023 , Edited by admin on Sat Dec 16 18:26:28 GMT 2023
|
PRIMARY | |||
|
300000042076
Created by
admin on Sat Dec 16 18:26:28 GMT 2023 , Edited by admin on Sat Dec 16 18:26:28 GMT 2023
|
PRIMARY | |||
|
11875
Created by
admin on Sat Dec 16 18:26:28 GMT 2023 , Edited by admin on Sat Dec 16 18:26:28 GMT 2023
|
PRIMARY | |||
|
C188586
Created by
admin on Sat Dec 16 18:26:28 GMT 2023 , Edited by admin on Sat Dec 16 18:26:28 GMT 2023
|
PRIMARY | |||
|
9815923
Created by
admin on Sat Dec 16 18:26:28 GMT 2023 , Edited by admin on Sat Dec 16 18:26:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)